Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Family history of hypertension, anthropometric parameters and markers of early atherosclerosis in young healthy individuals

Journal of Human Hypertension volume 23, pages 801–807 (2009)Cite this article

Abstract

The predisposition to thrombogenesis is increased in essential hypertension, and hypertensive patients are prone to develop more vulnerable atherosclerotic plaques. To evaluate the possible influence of family history of hypertension on some indicators of early atherosclerosis, we studied eighty-five healthy normotensive individuals with (FH+) or without (FH−) family history of essential hypertension by measuring metabolic profile and concentrations of P-selectin, interleukin 6 and matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1. In a subset of individuals, MMP-9 activity was assessed in monocytes by zymography, and TIMP-1 expression by western blot. As compared with FH− individuals, FH+ individuals had significantly higher P-selectin but similar interleukin-6 levels. Although no difference was observed in MMP-2 levels between the two groups, MMP-9 and TIMP-1 were higher in FH+ individuals, who also had higher intracellular MMP-9 levels and TIMP-1 protein expression. P-selectin (r=−0.32; P<0.01), MMP-9 (r=−0.37; P<0.001) and TIMP-1 (r=−0.23; P<0.05) levels were inversely related to high density lipoprotein (HDL) cholesterol. P-selectin was also directly related to serum triglycerides (r=0.30; P<0.01). We conclude that a positive family history of hypertension is associated with an initial increase in markers of inflammation and plaque instability in otherwise healthy young normotensive individuals, likely conveying a predisposition to develop early atherothrombosis.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sanz J, Moreno PR, Fuster V . The year in atherothrombosis. J Am Coll Cardiol 2007; 49: 1740–1749.

    Article  Google Scholar 

  2. Romero JR . Prevention of ischemic stroke: overview of traditional risk factors. Curr Drug Targets 2007; 8: 794–801.

    Article  CAS  Google Scholar 

  3. Neutel JM . Why lowering blood pressure is not enough: the hypertension syndrome and the clinical context of cardiovascular risk reduction. Heart Dis 2000; 2: 370–374.

    CAS  PubMed  Google Scholar 

  4. Messerli FH, Williams B, Ritz E . Essential hypertension. Lancet 2007; 370: 591–603.

    Article  CAS  Google Scholar 

  5. Helderman F, Segers D, de Crom R, Hierck BP, Poelmann RE, Evans PC et al. Effect of shear stress on vascular inflammation and plaque development. Curr Opin Lipidol 2007; 18: 527–533.

    Article  CAS  Google Scholar 

  6. Wilensky RL, Hamamdzic D . The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol 2007; 22: 545–551.

    Article  Google Scholar 

  7. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119–124.

    Article  CAS  Google Scholar 

  8. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY . Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75: 43–47.

    Article  CAS  Google Scholar 

  9. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY . Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764–769.

    CAS  PubMed  Google Scholar 

  10. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101.e1–1101.e8.

    Article  Google Scholar 

  11. Morita H, Khanal S, Rastogi S, Suzuki G, Imai M, Todor A et al. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol 2006; 290: H2522–H2527.

    Article  CAS  Google Scholar 

  12. Blann AD, Nadar SK, Lip GY . The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166–2179.

    Article  CAS  Google Scholar 

  13. Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY . Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian cardiac outcomes trial. J Intern Med 2007; 261: 384–391.

    Article  CAS  Google Scholar 

  14. Chironi G, Dosquet C, Del-Pino M, Denarie N, Megnien JL, Drouet L et al. Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men. Am J Hypertens 2006; 19: 1025–1031.

    Article  CAS  Google Scholar 

  15. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88: 3005–3010.

    Article  CAS  Google Scholar 

  16. Esmon CT . The impact of the inflammatory response on coagulation. Thromb Res 2004; 114: 321–327.

    Article  CAS  Google Scholar 

  17. Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N et al. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci (Lond) 2008; 114: 449–455.

    Article  CAS  Google Scholar 

  18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC VII Report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  19. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN . Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques: coexpression with intercellular adhesion molecule-1. Am J Pathol 1994; 144: 952–961.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Ridker PM, Buring JE, Rifai N . Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491–495.

    Article  CAS  Google Scholar 

  21. Yasmin, Wallace S, McEniery CM, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372–378.

    Article  CAS  Google Scholar 

  22. Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006; 26: 1799–1805.

    Article  CAS  Google Scholar 

  23. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY . Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17: 770–774.

    CAS  PubMed  Google Scholar 

  24. Nanni L, Romualdi C, Maseri A, Lanfranchi G . Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. Mol Cell Cardiol 2006; 41: 934–948.

    Article  CAS  Google Scholar 

  25. Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97: 175–180.

    Article  CAS  Google Scholar 

  26. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE . Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008; 41: 875–880.

    Article  CAS  Google Scholar 

  27. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J . MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121–1126.

    Article  CAS  Google Scholar 

  28. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM . Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674–682.

    Article  Google Scholar 

  29. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C . The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005; 183: 308–315.

    Article  CAS  Google Scholar 

  30. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962–971.

    Article  CAS  Google Scholar 

  31. Sie MP, Sayed-Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HA, Hofman A et al. Interleukin 6–174 G/C promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol 2006; 26: 212–217.

    Article  CAS  Google Scholar 

  32. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB . Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006; 15: 1914–1920.

    Article  CAS  Google Scholar 

  33. Pankow JS, Jacobs DR Jr, Steinberger J, Moran A, Sinaiko AR . Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care 2004; 27: 775–780.

    Article  CAS  Google Scholar 

  34. Ansell BJ . Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 2007; 100: 3–9.

    Article  Google Scholar 

  35. Gomez-Rosso L, Benitez MB, Fornari MC, Berardi V, Lynch S, Schreier L et al. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome. Atherosclerosis 2008; 199: 415–423.

    Article  CAS  Google Scholar 

  36. Li LJ, Geng SR, Yu CM . Endothelial dysfunction in normotensive Chinese with a family history of essential hypertension. Clin Exp Hypertens 2005; 27: 1–8.

    Article  Google Scholar 

  37. Nakamura G, Kugiyama K . Triglycerides and remnant particles as risk factors for coronary artery disease. Curr Atheroscler Rep 2006; 8: 107–110.

    Article  CAS  Google Scholar 

  38. Glowinska-Olszewska B, Urban M . Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007; 56: 799–805.

    Article  CAS  Google Scholar 

  39. Kralisch S, Bluher M, Tonjes A, Lossner U, Pashke R, Stumvoll M et al. Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur J Endocrinol 2007; 156: 257–261.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Pisa, Pisa, Italy

    A Solini, E Santini, S Madec & E Ferrannini

  2. Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy

    A Passaro

Authors
  1. A Solini
    View author publications

    Search author on:PubMed Google Scholar

  2. E Santini
    View author publications

    Search author on:PubMed Google Scholar

  3. A Passaro
    View author publications

    Search author on:PubMed Google Scholar

  4. S Madec
    View author publications

    Search author on:PubMed Google Scholar

  5. E Ferrannini
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to A Solini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Solini, A., Santini, E., Passaro, A. et al. Family history of hypertension, anthropometric parameters and markers of early atherosclerosis in young healthy individuals. J Hum Hypertens 23, 801–807 (2009). https://doi.org/10.1038/jhh.2009.26

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/jhh.2009.26

Keywords

This article is cited by

Search

Advanced search

Quick links